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Abstract
Background: Coronary heart disease (CHD) is the primary cause of death in individuals with chronic kidney disease (CKD),
but current equations for assessing coronary risk have low accuracy in this group. We have reported that the addition of a
genetic risk score (GRS) to the Framingham risk function improved its predictive capacity in the general population. The
aims of this study were to evaluate the association between this GRS and coronary events in the CKD population and to
determine whether the addition of the GRS to coronary risk prediction functions improves the estimation of coronary risk
at the earliest possible stages of kidney disease.
Methods: A total of 632 CKD patients, aged 35–74 years, who had Stage 4–5 CKD, were on dialysis, had a functioning renal
transplant or had returned to dialysis after transplant failure were included and followed up for a mean of 9.3 years. The
transitions between disease states and the development of coronary events were registered. The increase in predictive abil-
ity that was obtained by including the GRS was measured as the improvement in the C-statistic and as the net reclassifica-
tion index.
Results: The GRS was independently associated with the risk of CHD (hazards ratio 1.34; 95% confidence interval 1.04–1.71;
P¼0.022), especially in Stages 4 and 5 CKD, and kidney transplant patients. A coronary risk prediction function that incorpo-
rated chronic kidney disease (CKD) disease state, age, sex and the GRS had significantly greater predictive capacity (AUC
70.1, P¼0.01) and showed good reclassification (net reclassification improvement 28.6).
Conclusion: This new function, combining genetic and clinical data, identifies CKD patients with a high risk of coronary
events more accurately, allowing us to prevent such events more effectively.
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Introduction
Chronic kidney disease (CKD) is a public health problem world-
wide due to its high prevalence [1] and associated morbidity
and mortality [2, 3]. CKD is characterized by the progression
toward terminal uraemia, requiring treatment with dialysis or
kidney transplantation [4].
CKD patients experience 15–30 times greater age-adjusted
cardiovascular disease (CVD) mortality compared with the gen-
eral population [3, 4]. CVD mortality in individuals who are on
haemodialysis (HD) is high—20% annually [5]. This risk declines
following kidney transplantation but remains 3–5 times higher
than in the general population [6, 7].
Measures to prevent coronary heart disease (CHD) aim at low-
ering risk factor levels in those who are at the highest risk. CHD
risk estimation systems are used to make logical management
decisions and help avoid under- and overtreatment. CHD risk in
the general population is assessed using classical risk functions,
such as the Framingham risk score. However, these tools fail to
identify high-risk individuals accurately among CKD patients
[8, 9], perhaps because traditional risk factors alone do not
account for the morbidity and mortality that are associated with
CHD in CKD patients [9]. Several attempts to develop a disease-
specific risk score for CHD risk stratification in CKD have been
made, but none has attained widespread clinical use [10–12].
We have reported an association between CHD and a multilo-
cus genetic risk score (GRS), based on genetic variants that are
associated with CHD but not classical cardiovascular risk factors
(CVRFs) [13]. We have also shown that this GRS improves the pre-
dictive capacity of the Framingham risk function in the general
population [13] in terms of discrimination and reclassification.
The aims of the current study were to examine the associa-
tion between our coronary GRS and coronary events in individu-
als with CKD and determine whether the inclusion of this GRS
improves the predictive capacity of CHD risk tools at the earliest
stages of kidney disease.
Materials and methods
Patient sample, follow-up and phenotype definition
This prospective and observational study included 632 CKD
patients, aged 35–74 years, who had Stage 4 or 5 CKD (CKD 4/5
group), were receiving renal replacement therapy by HD or peri-
toneal dialysis (PD) (dialysis group), had a functioning renal
transplant (transplant group) or had returned to dialysis after
renal transplantation (transplant failure group); all patients had
been followed up for over 3 years by the nephrology service at
Marques de Valdecilla University Hospital.
The transitions between defined disease states (CKD 4/5,
dialysis, transplantation and transplant failure) and the devel-
opment of coronary events [fatal or non-fatal myocardial infarc-
tion (MI), angina pectoris and coronary revascularization] were
recorded for 620 patients during the follow-up. The identifica-
tion of these events was based on in-person attendance at the
clinic and on revision of the patients’ medical records. MI was
defined per American Heart Association/American College of
Cardiology (AHA/ACC) criteria [14], angina was based on the
presence of typical symptoms and an objective demonstration
of myocardial ischaemia (electrocardiography, coronary steno-
sis, etc.), and percutaneous coronary intervention and coronary
artery by-pass grafting were considered to be revascularization
procedures. Death due to CHD was determined following a
review of the mortality register—when the most likely cause of
death was CHD and no other cause could be ascribed.
Demographic and clinical parameters were also recorded,
including age, sex, race, height, weight, stage of renal disease,
disease aetiology, type of dialysis prior to transplant (HD or PD),
time in dialysis, previous transplants and the date of trans-
plantation and classical coronary risk factors (smoking history,
hypertension, hypercholesterolaemia and diabetes).
Biochemical parameters were measured during the first visit
to the nephrology department for CKD: total cholesterol, high-
density lipoprotein (HDL) cholesterol, low-density lipoprotein
(LDL) cholesterol, triglycerides, creatinine levels, glycaemia, gly-
cated haemoglobin (HbA1c), calcium, phosphorus, intact para-
thyroid hormone (iPTH), albumin and 24-h proteinuria. Systolic
and diastolic blood pressure was also recorded. Renal function
was estimated using the modified Modification of Diet in Renal
Disease (MDRD) equation [15].
This study was performed by the nephrology service of
Marque´s de Valdecilla University Hospital (Santander, Spain), and
the study protocol was approved by the institutional review board
of the same hospital. Written informed consent was obtained
from all subjects, and all clinical research was conducted per the
Declaration of Helsinki and the 2008 Istanbul Declaration.
Genotyping and construction of the multilocus risk
score
DNA samples were extracted from the patients’ blood using
standard methods and genotyped by Gendiag.exe (Esplugues de
Llobregat, Spain) using the Cardio inCode Score array (Ferrer
inCode, Barcelona, Spain), which is based on the Veracode
(Illumina, San Diego, CA, USA) and KASPar (KBioscience,
Hoddesdon, UK) technologies [16]. The overall percentage of
agreement between the chip and reference technology was 99.9%,
and the analytical sensitivity and specificity exceeded 98.6%.
Genetic variants that are associated with CHD but not CVRFs
(blood pressure, total cholesterol, LDL cholesterol, HDL choles-
terol, triglycerides, diabetes, smoking) were selected, and a
weighted multilocus GRS was constructed as described [13]. The
variants that we selected were: rs10455872 in LPA, rs12526453 in
PHACTR1, rs1333049 near CDKN2A/2B, rs17465637 in MIA3,
rs501120 in CXCL12, rs6725887 in WDR12, rs9818870 in MRAS,
rs9982601 near SCL5A3 and haplotype B of ALOX5AP, which
comprises rs10507391, rs17222842 and rs931505. The weight for
each variant was based on the individual estimated effect size
in the Coronary ARtery DIsease Genome-Wide Replication And
Meta-Analysis (CARDIoGRAM) study [17].
Estimation of 10-year coronary risk
Coronary risk was estimated using the modified Framingham
risk function for Spain Registre GironuˆU` del COR (REGICOR) [18].
This function includes age, sex, systolic and diastolic blood
pressure, total cholesterol, HDL cholesterol, smoking status and
diabetes status; the GRS was added to the function as published
[13], where indicated.
We derived three additional risk estimation models by
Cox regression analysis: Model 1 included age, sex and disease
state; Model 2 further incorporated HDL cholesterol,
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hypercholesterolaemia, diabetes, HbA1c and hypertension; and
Model 3 added MDRD, calcium, phosphorus, iPTH and albumin.
Statistical analysis
We used standard parametric and non-parametric methods to
compare the characteristics of the CKD sample. We tested for
associations between the incidence of coronary events and the
GRS [as a continuous variable in standard deviation (SD) units]
using Cox proportional hazards models, with adjustments for
CVRFs. The transition of disease states from CKD 4/5 to dialysis,
transplantation and transplant failure was considered a time-
dependent variable in the Cox regression models.
We used two statistics to assess the potential value of
including the GRS in a risk prediction model:
(i) Improvements in the discriminatory capacity of the model
were evaluated, based on the change in the C-statistic [19]
(ii) Improvements in reclassification were calculated using the
net reclassification improvement (NRI) index [20]. To this
end, we defined four risk categories (low, intermediate-low,
intermediate-high and high), with cut-off points that were
defined according to current guidelines (REGICOR: 0–5%,
5–10%, 10–15%, 15%) [13]. We calculated the expected
number of events at 10 years in each risk category using
Kaplan–Meier estimates [21] and used a bootstrapping
method to construct the confidence intervals for the NRI to
account for uncertainty in the Kaplan–Meier estimates, as
recommended by Steyerberg and Pencina [21]
All analyses were performed using the R statistical package
(version 2.11) [22].
Results
Sample characteristics, renal disease and coronary
events
Our cohort included 632 CKD patients (205 females and 427
males), with a median follow-up of 9.3 years and mean age of
53.4 years. We detected 73 coronary events during the follow-
up. In terms of progression of disease state, at the initial stage
(inclusion into the study), 220 individuals had CKD 4/5 (34.8%),
161 were undergoing dialysis (25.5%, 27 PD and 134 HD), 200 had
undergone a kidney transplantation (31.6%) and 51 had experi-
enced transplant failure (8.1%). Table 1 shows the rates of dis-
ease progression during the study period from the initial stage
in the 620 patients from whom we collected clinical data.
Compared with the general Spanish population [23], CKD
patients had a higher 10-year incidence of coronary events
(4.9% versus 13.2%, respectively; P < 0.001). Figure 1 shows the
incidence of coronary events of the study patients over time by
Kaplan–Meier analysis.
Table 2 shows the characteristics of this CKD sample. The
proportions of males, smokers, patients with a family history
of CVD and those with CKD 4/5 were higher in individuals
who had had a coronary event during the follow-up—these
subjects also had generally lower HDL cholesterol and iPTH
levels.
Association between GRS and coronary events in CKD
patients
The results of the multivariate-adjusted association analysis
between the time to CHD event and the clinical variables and
GRS are shown in Table 3. Age, male gender, smoking (current
or former) and levels of phosphorus and iPTH correlated directly
with CHD events in our CKD sample. In contrast, calcium, albu-
min, eGFR and kidney transplantation were inversely associ-
ated with CHD events.
The GRS (hereafter referred to as GRS-1) had a linear rela-
tionship with the incidence of CHD [hazards ratio (HR) per SD
unit 1.25; 95% confidence interval (CI) 1.00–1.56; P ¼ 0.048].
However, several variants in this GRS had missing value rates of
>9% (rs10455872, rs1050739, rs17222842 and rs9315051)
(Supplementary Table S1). Thus, a second GRS (GRS-2) was con-
structed, removing these variants. GRS-2 also correlated linearly
with the incidence of CHD (HR 1.34; 95% CI 1.04–1.71; P ¼ 0.022).
We detected a statistically significant interaction between
these GRSs and disease state, prompting us to stratify the
analysis by disease state (Table 4). GRS-2 was associated with
coronary events in patients with CKD-4/5 and transplant
patients. GRS-1 was also linked to coronary events in CKD 4/5
patients.
Table 1. Transition between disease states in patients during the
study period
Disease Stage Final stage (Number of patients)
Initial stage
Number
of patients Dialysis Transplant
Transplant
failure
CKD 4/5 220 112 82 26
Dialysis 161 40 102 19
Transplant 200 0 162 38
Transplant failure 51 0 0 51
Total 632 152 346 134
Fig. 1. The incidence of the coronary events along the time using the Kaplan–
Meier method. Event-free survival time with 95% CI. Solid line represents the
mean, and the dotted lines represent 95% CIs.
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Predictive capacity of the risk functions: discrimination
and reclassification
We analysed the predictive capacity of four CHD risk functions:
the Framingham tool, adapted to the Spanish population (the
REGICOR function), and three functions that were developed in
this study, incorporating the association between clinical varia-
bles and CHD events (Table 2). This analysis was performed
with and without the inclusion of GRSs (Table 5). Inclusion of
the GRSs into REGICOR significantly improved its predictive
capacity (C-statistic: GRS-1 66.8, P ¼ 0.027; GRS-2 66.0, P ¼ 0.04
compared with 63.5 for REGICOR alone) (Table 5, part A).
Because the association between the GRSs and CHD events
was only significant in patients with CKD 4/5 or a kidney trans-
plant, we analysed the predictive capacity of the CHD risk func-
tions with and without the GRS in these patient groups. Adding
GRS-2 significantly improved the predictive ability of REGICOR
with regard to discrimination [C-statistic: 60.1 (49.6–70.7) versus
52.5 1 (41.3–63.6), P ¼ 0.019, for REGICOR alone], but not reclassi-
fication [NRI ¼ 22.8% (10.0 to 55.5)] (Table 5, part B).
The predictive capacity of the newly developed CHD risk
functions was better than that of REGICOR. CHD risk function-1,
which included age, sex and disease state (CKD 4/5 or trans-
plant), had a C-statistic of 62.9 (95% CI 52.6–73.3), which
increased further on incorporation of GRS-2 [C-statistic 70.1
(61.3–78.8), P ¼ 0.013] (Table 5, part C). Moreover, CHD risk
function-1 with GRS-2 showed significant improvement with
regard to reclassification [NRI ¼ 28.6% (11.8–45.4)] (Table 5, part
C). The predictive capacity of CHD risk function-2 and CHD risk
function-3 was also significantly higher than that of REGICOR
alone, which improved by adding GRS-2, yielding a significant
improvement in discrimination and reclassification for CHD
risk function 2 þ GRS-2 versus CHD risk function 2 and a non-
significant improvement for CHD risk function 3 þ GRS-2 versus
CHD risk function 3 (Table 5, part C).
Discussion
Current recommendations on the prevention of coronary dis-
ease in clinical practice stress the need for interventions that
are based on an assessment of the individual’s global risk [24,
25]. Several risk-scoring systems, such as the Framingham risk
function, have been developed to determine an individual’s
global CHD risk. However, current CHD risk equations for the
general population fail to accurately identify high-risk individu-
als among CKD patients [8]. There has been extensive research
into the value of new biomarkers in identifying patients with an
increased risk of cardiovascular events in the general popula-
tion and in patients with CKD. An accurate assessment of cardi-
ovascular risk at an early stage would facilitate earlier, more
aggressive and focused treatment in persons with a greater
Table 2. Characteristics of the CKD study population according to the incidence of coronary events
Variables No CHD events CHD events
(n ¼ 547) (n ¼ 73) p-value
Age, n (SD) 53.0 (10.7) 55.3 (10.4) 0.074
Female, n (%) 190 (34.7) 13 (17.8) 0.006
Male, n (%) 357 (65.3) 60 (82.2) 0.006
Smoking status, n (%) 0.080
No 102 (58.6) 12 (37.5)
Yes 55 (31.6) 15 (46.9)
Ex-smoker 17 (9.77) 5 (15.6)
Total cholesterol, mmol/L (SD) 5,4 (1.2) 5.32 (1.5) 0.690
LDL cholesterol, mmol/L (SD) 3.26 (1.03) 3.15 (1.00) 0.451
HDL cholesterol, mmol/L (SD) 1.39 (0.26) 1.20 (0.43) 0.001
Systolic blood pressure, mmHg (SD) 141 (20.1) 140 (20.8) 0.955
Diastolic blood pressure, mmHg (SD) 82.2 (12) 82.6 (10.7) 0.808
Diabetes, n (%) 108 (19.7) 18 (24.7) 0.409
Hypertension, n (%) 463 (84.6) 61 (83.6) 0.946
Glycaemia, mg/dL (95% CI) 5.61 (5.11–5.88) 5.66 (5.05–6.6) 0.898
HbA1c, % (95% CI) 5.60 (5.20–6.30) 5.80 (5.35–6.60) 0.149
Family history, n (%) 91 (16.6) 41 (56.2) <0.001
Disease states, n (%)
CKD 4/5 182 (33.3) 38 (52.1) 0.002
Dialysis 141 (25.8) 15 (20.5) 0.402
Transplant 179 (32.7) 16 (21.9) 0.083
Transplant failure 45 (8.23) 4 (5.48) 0.557
MDRD, mL/min/1.73 m2 (95% CI) 19.2 (8.75–43.6) 20.5 (10.5–32.9) 0.911
Creatinine, lmol/L (95% CI) 274 (141–557) 291 (186–504) 0.811
Calcium, mmol/L (95% CI) 2.31 (2.1–2.44) 2.24 (2.1–2.4) 0.127
Phosphorus, mmol/L (95% CI) 1.36 (1.09–1.81) 1.39 (1.09–1.74) 0.927
iPTH, pmol/L (95% CI) 16.55 (7.64–32.57) 23.98 (10.06–41.59) 0.019
Albumin, lmol/L (95% CI) 5.94 (5.51–6.38) 5.94 (5.36–6.38) 0.791
Protein, urine, g/24 h 0.67 (0.10–2.55) 0.82 (0.23–2.37) 0.142
GRS-1, arbitrary unitsa (95% CI) 0.19 (0.83 to 0.72) 0.01 (0.621 to 1.02) 0.088
GRS-2, arbitrary unitsa, b (95% CI) 0.07 (0.70 to 0.67) 0.29 (0.24 to 0.84) 0.028
aGRS with standardized values (mean=0, typical deviation=1)
bAnalysed only in 597 individuals.
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need for preventive measures—ultimately to reduce event rates.
Several such markers have emerged, although their use in rou-
tine clinical applications has yet to be fully established.
Attempts to develop a disease-specific risk score for cardiac
risk stratification in CKD have also been made [10–12], most of
which have been focused on renal transplant candidates, but
none has achieved widespread clinical use. In contrast, we eval-
uated the association between our GRS and coronary events in
the CKD population and determined whether its addition to cor-
onary risk prediction tools improves coronary risk estimations
at the earliest possible stage of kidney disease—not merely at
the transplant stage.
The risk of developing CHD depends on several lifestyle
and genetic factors. Further, heritable factors account for as
much as 60% of the variation in risk [26]. Genome-wide associ-
ation study (GWAs) have identified several tag single nucleo-
tide polymorphisms (SNPs) in various loci throughout the
genome that are robustly associated with CHD. When com-
bined in a GRS—especially with clinical variables—these SNPs
become useful in predicting CHD events [27]. We used this
approach in a previous study [13] and in this work. Prompted
by the observation that our genetic panel improves the predic-
tive capacity of risk functions for the general population [13],
we examined whether this benefit could be obtained in CKD
patients, a population in whom CHD events must be predicted
more accurately.
Our data show that the inclusion of genetic variants signifi-
cantly improves the predictive capacity of the modified
Framingham risk function for Spain (REGICOR) in CKD patients,
effecting a rise in discrimination capacity and a non-significant
increase in reclassification. Moreover, a simpler function that
incorporates disease state, age, sex and our GRS for CKD 4/5 and
kidney transplant patients yields better results. Our function
provides 10-year prediction rates, applicable to CKD 4/5 and
renal transplant patients, and improves the predictive capacity
of classical coronary risk functions in a direct comparison with
a very good reclassification index.
Clinically, this new CHD risk function—combining disease
state, age, sex and our GRS—by identifying CKD patients who
are at risk more accurately, would facilitate earlier, more
aggressive, and focused preventive treatment of CKD 4/5 and
transplanted CKD patients, lowering the rates of clinically rele-
vant coronary events. CKD patients who are at high risk, accord-
ing to our novel tool, would be candidates for statin therapy,
based on their efficacy in decreasing LDL cholesterol levels and
global CHD risk. Statins have been proven to be effective for pri-
mary prevention of CVD in CKD patients [28].
Strengths and limitations
We highlight the following strengths of our study. We included
a population of CKD patients who were followed up for a mean
of 9.3 years, from kidney failure to dialysis, transplantation and
transplant failure, which allowed us to evaluate the robustness
of the GRS. Also, the variants that were included in our score
represent loci that have actual relevance to CHD risk and are
independent of CVRFs [13]; thus, our GRS provides complemen-
tary information to that provided by classical risk functions.
Finally, this GRS improves classical risk functions and allows us
Table 3. Bivariate association between clinical variables, genetic risk
score and time to coronary heart events
Variables HR 95% CI P-value
Age 1.42 1.14–1.76 0.002
Male 2.42 1.33–4.42 0.004
Smoking status
No Ref Ref Ref
Yes 2.28 1.07–4.87 0.034
Ex-smoker 2.27 0.80–6.46 0.123
Total cholesterol 0.93 0.88–0.97 0.002
LDL cholesterol 0.93 0.88–0.99 0.028
HDL cholesterol 0.72 0.61–0.85 <0.001
Systolic blood pressure 1.03 0.92–1.16 0.567
Diastolic blood pressure 0.87 0.71–1.06 0.159
Diabetes 1.53 0.91–2.59 0.110
Hypertension 1.78 0.72–4.41 0.215
Dyslipidaemia 1.58 0.99–2.49 0.056
Glycaemia 1.01 0.98–1.04 0.416
HbA1c 1.09 0.91–1.29 0.358
Disease states
CKD 4/5 Ref Ref Ref
Dialysis 1.10 0.52–2.30 0.803
Transplant 0.25 0.11–0.55 0.001
Transplant failure 0.47 0.19–1.14 0.094
MDRD 0.88 0.79–0.99 0.029
Creatinine 1.04 0.97–1.11 0.270
Calcium 0.82 0.67–0.99 0.041
Phosphorus 1.18 1.05–1.32 0.004
iPTH 1.01 1.00–1.01 0.003
Albumin 0.48 0.32–0.71 <0.001
Protein, urine 0.94 0.86–1.02 0.134
GRS-1 (per SD unit) 1.25 1.00–1.56 0.048
GRS-2 (per SD unit) 1.34 1.04–1.71 0.022
Table 4. Association of GRSs (as a continuous variable in SD units) with coronary events by disease state
GRS GRS-1 GRS-2
Variables HR (95% CI) P-value HR (95% CI) P-value
Age and sex-adjusted
CKD 4/5 3.0 (1.71–5.26) <0.001 2.05 (1.14–3.7) 0.017
Dialysis 1.03 (0.67–1.57) 0.899 0.92 (0.57–1.49) 0.739
Transplant 1.26 (0.88–1.8) 0.210 1.64 (1.10–2.45) 0.016
Transplant failure 0.88 (0.44–1.75) 0.711 1.12 (0.61–2.07) 0.713
Adjusted by estimated coronary risk according to the REGICOR function
CKD 4/5 2.86 (1.83–4.46) <0.001 2.33 (1.38–3.92) 0.002
Dialysis 1.12 (0.66–1.92) 0.672 0.87 (0.49–1.52) 0.618
Transplant 1.17 (0.88–1.58) 0.315 1.43 (1.03–1.99) 0.033
Transplant failure 0.90 (0.42–1.91) 0.779 1.23 (0.63–2.43) 0.544
For GRS composition, see Supplementary Table S1.
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to adapt them to the CKD population in the form of three new
predictive models, meriting further study.
The main limitations of this study are the size of the popula-
tion and the limited number of events that was observed. Also,
because this study was a single-centre report, replication of the
results is needed.
A relative limitation is that the missing individuals for some
of the variants accounted for the differences between GRS-1
and GRS-2. When GRS-1 was analysed on removal of the indi-
viduals with missing values, the performance of GRS-1 and
GRS-2 was identical (data not shown).
That we used a limited number of genetic variants could be
considered a limitation. However, in the general population, the
inclusion of more variants did not improve the results that were
obtained with the GRSs that were used in this study [29].
Although the GRS is not associated with cardiovascular
events/deaths in patients who are undergoing dialysis, this is
not a limitation. Arrhythmias, but not coronary disease, have
been shown to be responsible for 65% of all cardiac deaths, or
27% of all-cause mortality, in HD patients [30]. We have con-
firmed the strong association of the QTc interval and other clin-
ical data with mortality in CKD patients who are on HD [31].
In this study, we have characterized the association
between our multilocus GRS [13] and the incidence of CHD
events in a CKD cohort. Moreover, we found that a simple
function that combines age, sex and disease state with the
GRS predicts coronary events in CKD patients better, allowing
strategies to prevent the development of coronary events to be
implemented.
Supplementary data
Supplementary data are available online at http://ckj.
oxfordjournals
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